Avid Bioservices (CDMO) Stock

MINNEAPOLIS--(BUSINESS WIRE)--Punch & Associates intends to vote AGAINST proposed acquisition of Avid Bioservices, Inc. by GHO Capital and Ampersand Capital.

Dublin, Nov. 13, 2024 (GLOBE NEWSWIRE) -- The "Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis by Route of Administration (Topical, Transdermal, Others), Product, Service, End-use, and Country, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global semi-solid Dosage CDMO market is expected to reach USD 67.4 billion by 2030, and anticipated to grow at a CAGR of 11.80% from 2024 to 2030.

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Avid (NASDAQ: CDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, stockholders of Avid will receive only $12.50 per share in an all-cash transaction valued at approximatel.

NEW YORK , Nov. 7, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Avid Bioservices, Inc. (NASDAQ: CDMO) and its board of directors concerning the proposed acquisition of the company by GHO Capital Partners LLP and Ampersand Capital Partners. Stockholders will receive $12.50 for each share of Avid Bioservices stock that they hold.

MONSEY, New York, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Avid Bioservices (Nasdaq: CDMO) (“Avid”) to GHO Capital Partners (“GHO”) and Ampersand Capital Partners (“Ampersand”) for $12.50 per share in cash. The sale price is below the price target for Avid of $14.00 per share of Wall Street analyst Paul Knight of KeyBanc (source: TipRanks).

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO

TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the upcoming Craig-Hallum Bioprocessing Conference. Nick Green, president and chief executive officer, and Pramthesh Patel, Ph.D., vice president of process development, will be the featured speakers in a fireside chat at the conference, which will take place virtually on September 19, 2024.

Avid Bioservices, Inc. (NASDAQ:CDMO ) Q1 2025 Earnings Conference Call September 9, 2024 4:30 PM ET Company Participants Tim Brons - IR, Vida Strategic Partners Nick Green - President and CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Capital Group Paul Knight - KeyBanc Capital Markets Max Smock - William Blair Operator Good day and thank you for standing by. Welcome to the Avid Bioservices First Quarter Fiscal Year 2025 Financial Results Conference Call.

TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.